biostudies-literatureQuinn MCJScottish Randomised Trial in Ovarian CancerCancer Research UKNCATS NIH HHSCanadian Institutes of Health 3 ResearchEuropean Community&apos;s Seventh Framework ProgrammeKomen Foundation for the CureNew England-based Case-Control Study of Ovarian CancerPrincess Margaret Cancer Centre Foundation-BridgeDepartment of Defense CDMRPCancer Councils of New South WalesWomen&apos;s Cancer ProgramOvarian Cancer Research FundNational Health &amp; Medical Research Council of AustraliaImperial Experimental Cancer Research CentreCanadian Institutes of Health ResearchGeneral Clinical Research CenterU.S. Army Medical Research and Materiel CommandAustralian National Health and Medical Research Council Enabling GrantsU.S. National Institutes of Health 2Ovarian Cancer Prognosis and Lifestyle StudyUS Army Medical Research and Materiel CommandNational Center for Advancing Translational SciencesELAN Funds of the University of Erlangen-NurembergNationaal KankerplanNational Center for Research ResourcesNCRR NIH HHSPrincess Margaret Cancer CentrePost-Cancer GWAS initiativeNIHDepartment of DefenseNorth Carolina Ovarian Cancer StudyNational Health and Medical Research Council of AustraliaAmerican Cancer Society Early Detection ProfessorshipBreast Cancer Research FoundationHaukeland University Hospitalinnesota Ovarian Cancer AllianceUniversity of BergenMayo FoundationNCIMayo Clinic Ovarian Cancer Case-Control StudyUniversity of Sydney Cancer Research FundCIHR Team in Familial Risks of Breast CancerNCI NIH HHSNational Health and Medical Research CouncilMayo Clinic Case-Only Ovarian Cancer StudyGynaecological Oncology Biobank at WestmeadDepartment of Defence1669-1680https://www.ebi.ac.uk/biostudies/studies/S-EPMC8419101biostudies-literatureUnknown30(9)<h4>Background</h4>Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance.<h4>Methods</h4>We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy.<h4>Results</h4>We found seven SNPs at 12q24.33 associated with PFS (<i>P</i> < 5 × 10^-8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15-1.34; <i>P</i> = 1.47 × 10^-8). High expression of a nearby gene, <i>ULK1</i>, is associated with shorter PFS in EOC, and with poor prognosis in other cancersCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyIdentification of a Locus Near &lt;i&gt;ULK1&lt;/i&gt; Associated With Progression-Free Survival in Ovarian Cancer.PMC8419101DAMD17-02-1-0666628903400281C5047/A10692R01 CA 054419-10P50 CA159981UL1 TR001881DAMD17-02-1-0669U19 CA148537C12292/A11174C1287/A10118R01-CA149429C1281/A12014R01 CA054419P50-CA159981R01 CA1494291113867R01 CA128978P50 CA105009U19 CA148065C536/A6689R01- CA61107R01-CA5859816561N01-PC-67001R01 CA076016PI 12/01319UL1 TR000124P50-CA136393R01 CA12684115/RIG/1-16C1312/A15589P30-CA15083W81XWH-10-1-0341P50 CA136393P30 CA0150831U19 CA148112HEALTH-F2-2009-223175APP1120431R01-CA126841K07-CA80668R01-CA122443SIOP-06-258-01-COUNP30 CA008748K07 CA080668N01-CN-55424R01-CA058598CA1×01HG007491-01C8197/A16565R01 CA122443R01 CA248288APP1025142223175120950-SIOP-06-258-06-COUNR01 CA05859894 222 52M01 RR0000561U19 CA148065,R01 CA0950231996001U19 CA148537UL1TR000124ULTR00044512/RIG/1-17C1287/A 10710310670C536/A13086W81XWH-10-1-0280C5047/A8384U19-CA148112MO1- RR000056DAMD17-01-1-0729U19 CA148112CA128978APP1158083R01CA095023C5047/A15007R01-CA76016Heitz FGao BDork TKennedy CJLu YWebb PMShi WHinsley SPatch AMPharoah PDPfor Australian Ovarian Cancer Study GroupHogdall CKGlubb DMLarson MCWinham SJGharahkhani PBjorge LWoo MChenevix-Trench GMcCue KJohnatty SEFereday SQuinn MCJMoffitt MOng JSFasching PALester JEne GEVMacGregor SBeesley JModugno FO'Mara TACarney MEKjaer SKBerchuck AKarlan BYVelez Edwards DRCivitarese ATerry KLTyrer JPEdwards SLPejovic TJensen ABauman KdeFazio ABenitez JMay TBeckmann MWCunningham JMMoysich KSchildkraut JMHuntsman DGAGO Study GroupOPAL Study GroupDurst MCramer DWVergote IRiggan MJGarcia MJPfisterer JArmasu SMGoodman MTGlasspool RLambrechts DHogdall EFriedlander MBeeghly-Fadiel AMcCauley BMdu Bois AGoode ELfalseIdentification of a Locus Near &lt;i&gt;ULK1&lt;/i&gt; Associated With Progression-Free Survival in Ovarian Cancer.<h4>Background</h4>Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance.<h4>Methods</h4>We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy.<h4>Results</h4>We found seven SNPs at 12q24.33 associated with PFS (<i>P</i> < 5 × 10^-8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15-1.34; <i>P</i> = 1.47 × 10^-8). High expression of a nearby gene, <i>ULK1</i>, is associated with shorter PFS in EOC, and with poor prognosis in other cancers2021-01-01T00:00:00Z2021 Sep2026-04-08T18:22:21.336Z2026-04-08T09:10:46.793ZS-EPMC84191013416265810.1158/1055-9965.EPI-20-181710.1158/1055-9965.epi-20-1817